Imfinzi vs. Opdivo

Reviewed on 4/13/2021

Are Imfinzi and Opdivo the Same Thing?

Imfinzi (durvalumab) and Opdivo (nivolumab) are monoclonal antibodies used to treat different types of cancer.

Imfinzi is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy; or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

Opdivo is used to treat patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor; and to treat metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.

Side effects of Imfinzi and Opdivo that are similar include fatigue, constipation, decreased appetite, nausea, swelling of extremities, abdominal pain, musculoskeletal pain diarrhea/colitis, fever, shortness of breath, cough, and rash.

Side effects of Imfinzi that are different from Opdivo include urinary tract infection (UTI).

Side effects of Opdivo that are different from Imfinzi include itching, upper respiratory tract infection, vomiting, weakness, swelling, chest pain, joint pain, weight loss, irregular heartbeat, eye inflammation, infusion-related reactions, increased amylase, increased lipase, dizziness, numbness and tingling, skin peeling, skin redness, and psoriasis.

Both Imfinzi and Opdivo may interact with other drugs.

What Are Possible Side Effects of Imfinzi?

Common side effects of Imfinzi include:

  • fatigue,
  • musculoskeletal pain,
  • constipation,
  • decreased appetite,
  • nausea,
  • swelling of extremities,
  • urinary tract infection,
  • abdominal pain,
  • diarrhea/colitis,
  • fever,
  • shortness of breath,
  • cough, and
  • rash.

What Are Possible Side Effects of Opdivo?

Common side effects of Opdivo include:

  • fatigue
  • rash
  • itching
  • cough
  • upper respiratory tract infection
  • swelling of the extremities
  • shortness of breath
  • muscle pain
  • decreased appetite
  • nausea
  • vomiting
  • constipation
  • diarrhea
  • weakness
  • swelling
  • fever
  • abdominal pain
  • chest pain
  • joint pain
  • weight loss
  • irregular heartbeat
  • eye inflammation
  • infusion-related reactions
  • increased amylase
  • increased lipase
  • dizziness
  • numbness and tingling
  • skin peeling
  • skin redness and
  • psoriasis.

SLIDESHOW

Skin Cancer Symptoms, Types, Images See Slideshow

What Is Imfinzi?

Imfinzi (durvalumab) is a programmed death-ligand 1 (PD-L1) blocking antibody indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who have disease progression during or following platinum-containing chemotherapy; or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy.

What Is Opdivo?

Opdivo (nivolumab) is a human monoclonal antibody used to treat patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor; and to treat metastatic squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.

What Drugs Interact With Imfinzi?

Imfinzi may interact with other drugs. Tell your doctor all medications and supplements you use.

What Drugs Interact With Opdivo?

Opdivo may interact with other drugs. Tell your doctor all medications and supplements you use.

How Should Imfinzi be Taken?

Administer Imfinzi in a dose of 10 mg/kg as an intravenous infusion over 60 minutes every 2 weeks.

How Should Opdivo be Taken?

The recommended dose of Opdivo depends on the condition being treated and whether Opdivo is being administered as a single agent or in combination with another drug.

Disclaimer

All drug information provided on RxList.com is sourced directly from drug monographs published by the U.S. Food and Drug Administration (FDA).

Any drug information published on RxList.com regarding general drug information, drug side effects, drug usage, dosage, and more are sourced from the original drug documentation found in its FDA drug monograph.

Drug information found in the drug comparisons published on RxList.com is primarily sourced from the FDA drug information. The drug comparison information found in this article does not contain any data from clinical trials with human participants or animals performed by any of the drug manufacturers comparing the drugs.

The drug comparisons information provided does not cover every potential use, warning, drug interaction, side effect, or adverse or allergic reaction. RxList.com assumes no responsibility for any healthcare administered to a person based on the information found on this site.

As drug information can and will change at any time, RxList.com makes every effort to update its drug information. Due to the time-sensitive nature of drug information, RxList.com makes no guarantees that the information provided is the most current.

Any missing drug warnings or information does not in any way guarantee the safety, effectiveness, or the lack of adverse effects of any drug. The drug information provided is intended for reference only and should not be used as a substitute for medical advice.

If you have specific questions regarding a drug’s safety, side effects, usage, warnings, etc., you should contact your doctor or pharmacist, or refer to the individual drug monograph details found on the FDA.gov or RxList.com websites for more information.

You may also report negative side effects of prescription drugs to the FDA by visiting the FDA MedWatch website or calling 1-800-FDA-1088.

References
AstraZeneca. Imfinzi Production Information.

https://www.imfinzi.com/

Bristol Myers Squibb. Opdivo Drug Information.

https://www.opdivo.com/

Health Solutions From Our Sponsors